Compare The Vita Coco Company Inc (COCO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs TG Therapeutics Inc — how do they compare? The Vita Coco Company Inc trades at $64.92 (market cap $3.73B), while TG Therapeutics Inc trades at $50.41 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 2× The Vita Coco Company Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, The Vita Coco Company Inc nearer its low. Which is the better fit depends on your goals.
| COCO | TGTX | |
|---|---|---|
Market Cap | $3.73B | $7.64B |
Sector | Technology | Health |
52-Week High | $84.02 | $59.06 |
52-Week Low | $32.37 | $26.94 |
Enterprise Value | $3.47B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COCO trades at $64.96, up 3.47% on the day, with strong earnings beats in Q1 and Q2 2026 driving momentum. The stock shows a bearish technical signal but bullish oscillators, with support near $62 and resistance at $65. Recent Q2 results featured 28% revenue growth and raised 2026 guidance, supported by the Copra acquisition and international expansion.
Outlook is positive with 60% analyst buy ratings and an $80.67 price target, though high valuation multiples and cost pressures pose risks. Growth catalysts include brand demand and market share gains, while investor sentiment is bolstered by defensive stock attributes amid economic uncertainty.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
